Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company founded in 2015 with a dedicated focus on driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. The company's multi-patented ZetaMet™ technology, exclusively licensed from the State University of New York in 2016, is designed to suspend cancer, inhibit pain, and regenerate bone, offering new hope for patients. The novel therapy, a drug-eluting implant technology, has successfully passed its preclinical trials and is being prepared for its first human clinical trial in Q4 2021. Zetagen's pipeline also includes other oncologic treatments for Skeletal Related Events (SREs) such as ZetaMet Flowable™, and ancillary osteologic treatments including ZetaFuse™, ZetaSet™, ZetaDent™, and ZetaBase™. The company has garnered support through Series A funding, private and angel investors, as well as Phase I and Phase II NIH research grants. In August 2023, Zetagen Therapeutics received $9.79M in Series B investment from notable investors including New York Ventures of Empire State Development and Consolidated Investment Group. Based in the United States, Zetagen is poised to make significant strides in the Health Care industry, with its cutting-edge therapeutic approaches and promising clinical developments.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $9.79M | 2 | New York Ventures, Consolidated Investment Group | 11 Aug 2023 |
| Series B | Unknown | 1 | New York Ventures | 20 Oct 2022 |
| Grant | $2.00M | 1 | National Cancer Institute | 13 Dec 2021 |
| Seed Round | $840.00K | - | 27 Dec 2019 | |
| Seed Round | Unknown | 1 |
|
12 Jun 2018 |
No recent news or press coverage available for Zetagen Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
